Allan Blemings's research while affiliated with Imperial College London and other places

Publications (4)

Article
Full-text available
Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desperate need for novel treatment avenues to be explored. Here, we present (1) an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for AN...
Article
Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a...
Article
Full-text available
Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such accounts are potentially biased by the placebo effect. This study used a ‘self-blinding’ citizen science initiative, where participants were given online instructions on how to in...
Article
Full-text available
Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such accounts are potentially biased by the placebo effect. This study used a ‘self-blinding’ citizen science initiative, where participants were given online instructions on how to in...

Citations

... In contrast to the more robust evidence available for ketamine, most of the findings for SPs are anecdotal. These promising preliminary results nevertheless suggest that SPs may be useful in treating disorders characterized by maladaptive cognitive distortions, like OCD and anorexia nervosa (Foldi et al., 2020;Moreno et al., 2006;Spriggs et al., 2021). Given that SPs also preliminarily appear to mitigate tobacco, alcohol, cannabis, stimulant, and opioid use (Davis et al., 2018;Garcia-Romeu et al., 2019;Johnson et al., 2014;Jones and Nock, 2022;Noller et al., 2018), the anti-addictive potential of SPs also warrants additional investigation. ...
... Further support comes from the widely used practice of microdosing in which doses of psilocybin that are only a fraction (one tenth or less) of the psychedelic dose are taken by individuals in a nonmedicinal context. While results are not consistent and comprehensive studies are lacking, there is evidence that microdosing may have positive effects on mood, creative processes, and energy [168,169]. In a recent large internet-based study psilocybin was the most frequently microdosed psychedelic agent. ...
... However, although favouring psilocybin over escitalopram on secondary outcomes, the primary efficacy endpoint (self-reported Inventory of Depressive Symptomatology) did not reach statistical significance. 8 Given that a rapid decrease in symptom severity was observed in both intervention arms, it is possible that the psychological support and the low dose of psilocybin may have contributed significantly to the therapeutic effect. Lastly, a multi-centric trial investigating efficacy of 25 mg, 10 mg, and 1 mg of psilocybin in patients with treatment-resistant depression reported significant symptom reduction for the 25 mg treatment condition 3 weeks after baseline. ...
... Restrictive drug policies make placebo-controlled studies on CBMPs difficult and expensive to conduct in laboratory settings due to the need for home office licences and intensive regulatory oversight. Citizenscience approaches may help to overcome these challenges (48). Citizen science involves individuals implementing their own placebo control at home, using their own acquired medical cannabis products, following online instructions to conduct self experimentation over a given time period with self-reported clinical scales to assess the value of the intervention. ...